• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Mutant selection window of clarithromycin for clinical isolates of Helicobacter pylori.幽门螺杆菌临床分离株克拉霉素耐药突变选择窗。
BMC Microbiol. 2019 Aug 5;19(1):176. doi: 10.1186/s12866-019-1558-8.
2
[Prevalence and mechanism of Helicobacter pylori resistance to clarithromycin in children].[儿童幽门螺杆菌对克拉霉素耐药的患病率及机制]
Zhonghua Er Ke Za Zhi. 2004 Nov;42(11):850-3.
3
PCR-RFLP detection of point mutations A2143G and A2142G in 23S rRNA gene conferring resistance to clarithromycin in Helicobacter pylori strains.PCR-RFLP检测幽门螺杆菌菌株中23S rRNA基因导致对克拉霉素耐药的点突变A2143G和A2142G
Acta Biochim Pol. 2014;61(2):311-5. Epub 2014 Jun 13.
4
Droplet Digital PCR-Based Detection of Clarithromycin Resistance in Helicobacter pylori Isolates Reveals Frequent Heteroresistance.基于液滴数字 PCR 的幽门螺杆菌分离株克拉霉素耐药性检测显示频繁的异质性耐药。
J Clin Microbiol. 2018 Aug 27;56(9). doi: 10.1128/JCM.00019-18. Print 2018 Sep.
5
[Changing patterns of antibiotic resistance of Helicobacter pylori in patients with peptic ulcer disease].[消化性溃疡病患者幽门螺杆菌抗生素耐药模式的变化]
Korean J Gastroenterol. 2007 Dec;50(6):356-62.
6
A 9 year study of clarithromycin and metronidazole resistance in Helicobacter pylori from Spanish children.一项针对西班牙儿童幽门螺杆菌对克拉霉素和甲硝唑耐药性的9年研究。
J Antimicrob Chemother. 2001 Aug;48(2):295-7. doi: 10.1093/jac/48.2.295.
7
Increasing antimicrobial resistance to clarithromycin and metronidazole in pediatric Helicobacter pylori infection in southern Taiwan: A comparison between two decades.台湾南部儿童幽门螺杆菌感染中克拉霉素和甲硝唑耐药性的增加:二十年的对比。
Helicobacter. 2019 Oct;24(5):e12633. doi: 10.1111/hel.12633. Epub 2019 Jul 11.
8
High percentage of clarithromycin and metronidazole resistance in Helicobacter pylori clinical isolates obtained from Spanish children.从西班牙儿童中分离出的幽门螺杆菌临床菌株对克拉霉素和甲硝唑的耐药率很高。
Rev Esp Quimioter. 2009 Jun;22(2):88-92.
9
The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance.抗菌药物的使用与原发性幽门螺杆菌耐药率之间的关系。
Helicobacter. 2002 Oct;7(5):306-9. doi: 10.1046/j.1523-5378.2002.00096.x.
10
Occurrence of Mutations in the Antimicrobial Target Genes Related to Levofloxacin, Clarithromycin, and Amoxicillin Resistance in Helicobacter pylori Isolates from Buenos Aires City.布宜诺斯艾利斯市幽门螺杆菌分离株中与左氧氟沙星、克拉霉素和阿莫西林耐药相关的抗菌靶基因的突变情况
Microb Drug Resist. 2017 Apr;23(3):351-358. doi: 10.1089/mdr.2015.0361. Epub 2016 Jul 8.

引用本文的文献

1
The effect of antibiotic selection on collateral effects and evolvability of uropathogenic .抗生素选择对尿路致病性的附带效应和进化能力的影响
NPJ Antimicrob Resist. 2024;2(1):19. doi: 10.1038/s44259-024-00037-4. Epub 2024 Jul 17.
2
The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications.抗生素对幽门螺杆菌感染的潜在用途:生物制药意义
Front Pharmacol. 2022 Jun 27;13:917184. doi: 10.3389/fphar.2022.917184. eCollection 2022.
3
Using Probiotics as Supplementation for Antibiotic Therapy.使用益生菌作为抗生素治疗的补充。
Int J Mol Sci. 2020 Feb 8;21(3):1136. doi: 10.3390/ijms21031136.

本文引用的文献

1
Resistance to clarithromycin and gastroenterologist's persistence roles in nomination for Helicobacter pylori as high priority pathogen by World Health Organization.对克拉霉素的耐药性和胃肠病学家在世界卫生组织将幽门螺杆菌列为高优先病原体过程中的提名坚持作用。
World J Gastroenterol. 2017 Sep 21;23(35):6379-6384. doi: 10.3748/wjg.v23.i35.6379.
2
Usefulness of detection of clarithromycin-resistant Helicobacter pylori from fecal specimens for young adults treated with eradication therapy.粪便标本检测克拉霉素耐药幽门螺杆菌在接受根除治疗的年轻成年人中的应用。
Helicobacter. 2017 Oct;22(5). doi: 10.1111/hel.12396. Epub 2017 May 22.
3
Detection of Helicobacter pylori and the genotypes of resistance to clarithromycin and the heterogeneous genotype to this antibiotic in biopsies obtained from symptomatic children.在有症状儿童的活检组织中检测幽门螺杆菌、克拉霉素耐药基因型及该抗生素的异质性基因型。
Diagn Microbiol Infect Dis. 2017 Feb;87(2):150-153. doi: 10.1016/j.diagmicrobio.2016.03.001. Epub 2016 Mar 2.
4
Human Lysozyme Synergistically Enhances Bactericidal Dynamics and Lowers the Resistant Mutant Prevention Concentration for Metronidazole to Helicobacter pylori by Increasing Cell Permeability.人溶菌酶通过增加细胞通透性协同增强杀菌动力学并降低甲硝唑对幽门螺杆菌的耐药突变预防浓度。
Molecules. 2016 Oct 28;21(11):1435. doi: 10.3390/molecules21111435.
5
Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.幽门螺杆菌感染的管理——马斯特里赫特 V/佛罗伦萨共识报告。
Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288. Epub 2016 Oct 5.
6
The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use.幽门螺杆菌根除失败与既往抗生素使用之间的关系。
Dig Liver Dis. 2016 Apr;48(4):385-90. doi: 10.1016/j.dld.2015.12.001. Epub 2015 Dec 15.
7
Impacts of H. pylori mixed-infection and heteroresistance on clinical outcomes.幽门螺杆菌混合感染及异质性耐药对临床结局的影响。
Gastroenterol Hepatol Bed Bench. 2015 Spring;8(Suppl 1):S1-5.
8
Helicobacter pylori infection in Chinese patients with atrial fibrillation.中国房颤患者的幽门螺杆菌感染
Clin Interv Aging. 2015 Apr 28;10:813-9. doi: 10.2147/CIA.S72724. eCollection 2015.
9
Treatment of Helicobacter pylori infection: Past, present and future.幽门螺杆菌感染的治疗:过去、现在与未来。
World J Gastrointest Pathophysiol. 2014 Nov 15;5(4):392-9. doi: 10.4291/wjgp.v5.i4.392.
10
Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence.合理的幽门螺杆菌治疗:基于证据的医学,而不是基于证据的医学。
Clin Gastroenterol Hepatol. 2014 Feb;12(2):177-86.e3; Discussion e12-3. doi: 10.1016/j.cgh.2013.05.028. Epub 2013 Jun 8.

幽门螺杆菌临床分离株克拉霉素耐药突变选择窗。

Mutant selection window of clarithromycin for clinical isolates of Helicobacter pylori.

机构信息

College of Basic Medical Sciences, Army Medical University, Chongqing, 400042, China.

Department of Gastroenterology, Daping Hospital, Army Medical University, 10 Changjiang Branch Road, Chongqing, 400042, China.

出版信息

BMC Microbiol. 2019 Aug 5;19(1):176. doi: 10.1186/s12866-019-1558-8.

DOI:10.1186/s12866-019-1558-8
PMID:31382897
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6683470/
Abstract

BACKGROUND

Clarithromycin-resistance is becoming a global health concern in the treatment of Helicobacter pylori (H. pylori). The mutant prevention concentration (MPC) represent the propensities of antimicrobial agents to select resistant mutants. The concentration range between the minimum inhibitory concentration (MIC) and the MPC is defined as mutant selection window (MSW). In this study, we aimed to determine the cause of increasing clarithromycin resistance by investigating the MSW for clinical isolates of H. pylori.

RESULTS

A retrospective subgroup, which included 68 clarithromycin-sensitive H. pylori strains, was selected from a double-blind trial. The MICs and MPCs were determined using agar plate assays. Genotypic tests were performed using Sanger sequencing. All isolates were wild-type, and 33.82% (23/68) had a 0.016 mg/L MIC, 45.59% (31/68) had a 0.031 mg/L MIC, 16.18% (11/68) had a 0.062 ≤ MIC ≤ 0.125 mg/L, and 4.41% (3/68) had a 0.25 mg/L MIC. The MPC (mg/L) of the isolates were: 0.062/0.125, 0.125/0.5, 0.25/0.25 and 1/2, respectively. The MPCs showed a moderate correlation with the MICs (r = 0.65, P < 0.0001). Using published data and MPC, we calculated the time inside the MSW (T) for low- and high-dose (200 or 500 mg bid) clarithromycin that were 6 and 0 h, 24 and 4 h, 15 and 2 h, 5 and 17 h for the strains with MICs (mg/L) of 0.016, 0.031, 0.062-0.125, and 0.25, respectively.

CONCLUSIONS

This study showed that in the clarithromycin-sensitive clinical isolates of H. pylori, low-dose clarithromycin may lead to decreased drug sensitivity or even clarithromycin resistance; strains with a 0.25 mg/L MIC display a high risk of treatment failure.

摘要

背景

克拉霉素耐药性在幽门螺杆菌(H. pylori)的治疗中成为一个全球健康关注问题。突变预防浓度(MPC)代表了抗菌药物选择耐药突变体的倾向。最低抑菌浓度(MIC)和 MPC 之间的浓度范围定义为突变选择窗(MSW)。在这项研究中,我们旨在通过研究 H. pylori 临床分离株的 MSW 来确定克拉霉素耐药性增加的原因。

结果

从一项双盲试验中选择了一个包含 68 株克拉霉素敏感的 H. pylori 菌株的回顾性亚组。使用琼脂平板测定法测定 MIC 和 MPC。使用 Sanger 测序进行基因测试。所有分离株均为野生型,33.82%(23/68)的 MIC 为 0.016mg/L,45.59%(31/68)的 MIC 为 0.031mg/L,16.18%(11/68)的 MIC 为 0.062mg/L ≤MIC ≤0.125mg/L,4.41%(3/68)的 MIC 为 0.25mg/L。分离株的 MPC(mg/L)分别为:0.062/0.125、0.125/0.5、0.25/0.25 和 1/2。MPC 与 MIC 呈中度相关(r=0.65,P<0.0001)。使用已发表的数据和 MPC,我们计算了低剂量(200 或 500mg bid)和高剂量(200 或 500mg bid)克拉霉素在 MIC(mg/L)分别为 0.016、0.031、0.062-0.125 和 0.25 的菌株中处于 MSW 内的时间(T),分别为 6 和 0 小时、24 和 4 小时、15 和 2 小时、5 和 17 小时。

结论

本研究表明,在克拉霉素敏感的 H. pylori 临床分离株中,低剂量克拉霉素可能导致药物敏感性降低甚至克拉霉素耐药;MIC 为 0.25mg/L 的菌株治疗失败的风险较高。